These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 35477798)

  • 21. The
    Tsai MM; Chen L; Baumann MH; Canals M; Javitch JA; Lane JR; Shi L
    bioRxiv; 2023 Nov; ():. PubMed ID: 38014284
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antinociceptive and Discriminative Stimulus Effects of Six Novel Psychoactive Opioid Substances in Male Rats.
    Walker EA; Chambers C; Korber MG; Tella SR; Prioleau C; Fang L
    J Pharmacol Exp Ther; 2021 Oct; 379(1):1-11. PubMed ID: 34244232
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Receptor reserve and affinity of mu opioid agonists in mouse antinociception: correlation with receptor binding.
    Zernig G; Issaevitch T; Broadbear JH; Burke TF; Lewis JW; Brine GA; Woods JH
    Life Sci; 1995; 57(23):2113-25. PubMed ID: 7475964
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proliferation of Novel Synthetic Opioids in Postmortem Investigations After Core-Structure Scheduling for Fentanyl-Related Substances.
    Papsun DM; Krotulski AJ; Logan BK
    Am J Forensic Med Pathol; 2022 Dec; 43(4):315-327. PubMed ID: 36103391
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elucidating the harm potential of brorphine analogues as new synthetic opioids: Synthesis, in vitro, and in vivo characterization.
    Vandeputte MM; Bilel S; Tirri M; Corli G; Bassi M; Layle NK; Fantinati A; Walther D; Iula DM; Baumann MH; Stove CP; Marti M
    Neuropharmacology; 2024 Dec; 260():110113. PubMed ID: 39154855
    [TBL] [Abstract][Full Text] [Related]  

  • 26.
    Berardinelli D; Taoussi O; Carlier J; Tini A; Zaami S; Sundermann T; Busardò FP; Auwärter V
    Clin Chem Lab Med; 2024 Jul; 62(8):1580-1590. PubMed ID: 38311816
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro characterization of new psychoactive substances at the μ-opioid, CB1, 5HT
    Åstrand A; Guerrieri D; Vikingsson S; Kronstrand R; Green H
    Forensic Sci Int; 2020 Dec; 317():110553. PubMed ID: 33160102
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rapid screening of 2-benzylbenzimidazole nitazene analogs in suspect counterfeit tablets using Raman, SERS, DART-TD-MS, and FT-IR.
    Kimani MM; Kern S; Lanzarotta A; Thatcher M; Lorenz LM; Smith SW; Collins M; Howe GW; Wetherby AE
    Drug Test Anal; 2023 May; 15(5):539-550. PubMed ID: 36648419
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro μ-opioid receptor activation potential of U10 and β-U10, positional isomers of the synthetic opioid naphthyl U-47700.
    Vandeputte MM; Stove CP
    Drug Test Anal; 2024 Mar; 16(3):323-326. PubMed ID: 37482925
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of highly potent synthetic opioid nitazene analogs and their positional isomers.
    Kanamori T; Okada Y; Segawa H; Yamamuro T; Kuwayama K; Tsujikawa K; Iwata YT
    Drug Test Anal; 2023 Apr; 15(4):449-457. PubMed ID: 36437623
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Binding preference at the μ-opioid receptor underlies distinct pharmacology of cyclopropyl versus valeryl analogs of fentanyl.
    Xie B; Le Rouzic VP; Goldberg A; Tsai MM; Chen L; Zhang T; Sinha A; Pan YX; Baumann MH; Shi L
    Neuropharmacology; 2023 Apr; 227():109442. PubMed ID: 36731721
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacological characterization of novel synthetic opioids (NSO) found in the recreational drug marketplace.
    Baumann MH; Majumdar S; Le Rouzic V; Hunkele A; Uprety R; Huang XP; Xu J; Roth BL; Pan YX; Pasternak GW
    Neuropharmacology; 2018 May; 134(Pt A):101-107. PubMed ID: 28807672
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Affinity, potency, efficacy, selectivity, and molecular modeling of substituted fentanyls at opioid receptors.
    Eshleman AJ; Nagarajan S; Wolfrum KM; Reed JF; Nilsen A; Torralva R; Janowsky A
    Biochem Pharmacol; 2020 Dec; 182():114293. PubMed ID: 33091380
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Etonitazene: an opioid selective for the mu receptor types.
    Moolten MS; Fishman JB; Chen JC; Carlson KR
    Life Sci; 1993; 52(18):PL199-203. PubMed ID: 8097861
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness comparisons of G-protein biased and unbiased mu opioid receptor ligands in warm water tail-withdrawal and drug discrimination in male and female rats.
    Schwienteck KL; Faunce KE; Rice KC; Obeng S; Zhang Y; Blough BE; Grim TW; Negus SS; Banks ML
    Neuropharmacology; 2019 May; 150():200-209. PubMed ID: 30660628
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Naloxone Use in Novel Potent Opioid and Fentanyl Overdoses in Emergency Department Patients.
    Amaducci A; Aldy K; Campleman SL; Li S; Meyn A; Abston S; Culbreth RE; Krotulski A; Logan B; Wax P; Brent J; Manini AF;
    JAMA Netw Open; 2023 Aug; 6(8):e2331264. PubMed ID: 37642962
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discriminative stimulus effects of two doses of fentanyl in rats: pharmacological selectivity and effect of training dose on agonist and antagonist effects of mu opioids.
    Zhang L; Walker EA; Sutherland J; Young AM
    Psychopharmacology (Berl); 2000 Feb; 148(2):136-45. PubMed ID: 10663428
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel fentanyl-based dual μ/δ-opioid agonists for the treatment of acute and chronic pain.
    Podolsky AT; Sandweiss A; Hu J; Bilsky EJ; Cain JP; Kumirov VK; Lee YS; Hruby VJ; Vardanyan RS; Vanderah TW
    Life Sci; 2013 Dec; 93(25-26):1010-6. PubMed ID: 24084045
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activation of the μ-opioid receptor by alicyclic fentanyls: Changes from high potency full agonists to low potency partial agonists with increasing alicyclic substructure.
    Åstrand A; Vikingsson S; Jakobsen I; Björn N; Kronstrand R; Gréen H
    Drug Test Anal; 2021 Jan; 13(1):169-174. PubMed ID: 32749741
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, synthesis, and preliminary evaluation of a potential synthetic opioid rescue agent.
    Hedrick SL; Luo D; Kaska S; Niloy KK; Jackson K; Sarma R; Horn J; Baynard C; Leggas M; Butelman ER; Kreek MJ; Prisinzano TE
    J Biomed Sci; 2021 Sep; 28(1):62. PubMed ID: 34503531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.